TACSTD2 and neoplasm: The identification of new targets, such as additional tumor-associated antigens or signaling pathways, could greatly expand the therapeutic spectrum, particularly for patients who are unresponsive to existing targets such as trophoblast cell-surface antigen 2 (Trop2).